Patient characteristics at commencement of CTD chemotherapy
| . | Value . |
|---|---|
| Age, y, median (range) | 60 (29-81) |
| Sex, male-to-female ratio | 0.9:1 |
| Monoclonal light chain, no. patients (%) | |
| κ | 23 (31) |
| λ | 52 (69) |
| Hemoglobin level, g/L, median (range) | 12.0 (8.2-18.9) |
| Platelet count, × 109/L, median (range) | 248 (89-875) |
| Creatinine level, μM, median (range) | 96 (56-ESRD) |
| Albumin level, g/L, median (range) | 38 (14-55) |
| Bilirubin level, mM, median (range) | 8 (4-64) |
| Alkaline phosphatase level, IU/L, median (range) | 110 (43-1357) |
| 24-h proteinuria, g/24 h, median (range) | 1.8 (<0.1-11) |
| Creatinine clearance, mL/min, median (range) | 58 (ESRD-140) |
| Organ involvement, no. patients (%) | |
| Liver, consensus criteria | 18 (24) |
| Liver, SAP scintigraphy | 32 (43) |
| Renal, consensus criteria | 48 (64) |
| Renal, SAP scintigraphy | 56 (75) |
| Cardiac, any involvement | 44 (59) |
| Cardiac, IVS ≥ 15 mm | 25 (33) |
| Peripheral neuropathy | 0 |
| Total number of organs, international consensus criteria, no. patients (%) | |
| 1 | 16 (22) |
| 2 | 34 (45) |
| 3 or more | 25 (33) |
| ECOG performance status, no. patients (%) | |
| No more than 1 | 29 (39) |
| 2 | 36 (48) |
| At least 3 | 10 (13) |
| . | Value . |
|---|---|
| Age, y, median (range) | 60 (29-81) |
| Sex, male-to-female ratio | 0.9:1 |
| Monoclonal light chain, no. patients (%) | |
| κ | 23 (31) |
| λ | 52 (69) |
| Hemoglobin level, g/L, median (range) | 12.0 (8.2-18.9) |
| Platelet count, × 109/L, median (range) | 248 (89-875) |
| Creatinine level, μM, median (range) | 96 (56-ESRD) |
| Albumin level, g/L, median (range) | 38 (14-55) |
| Bilirubin level, mM, median (range) | 8 (4-64) |
| Alkaline phosphatase level, IU/L, median (range) | 110 (43-1357) |
| 24-h proteinuria, g/24 h, median (range) | 1.8 (<0.1-11) |
| Creatinine clearance, mL/min, median (range) | 58 (ESRD-140) |
| Organ involvement, no. patients (%) | |
| Liver, consensus criteria | 18 (24) |
| Liver, SAP scintigraphy | 32 (43) |
| Renal, consensus criteria | 48 (64) |
| Renal, SAP scintigraphy | 56 (75) |
| Cardiac, any involvement | 44 (59) |
| Cardiac, IVS ≥ 15 mm | 25 (33) |
| Peripheral neuropathy | 0 |
| Total number of organs, international consensus criteria, no. patients (%) | |
| 1 | 16 (22) |
| 2 | 34 (45) |
| 3 or more | 25 (33) |
| ECOG performance status, no. patients (%) | |
| No more than 1 | 29 (39) |
| 2 | 36 (48) |
| At least 3 | 10 (13) |
ESRD indicates end-stage renal disease; IVS, interventricular septal thickness.